These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 39373732)
1. Impact of low HER2 expression on response to CDK4/6 inhibitor treatment in advanced HR + /HER2- breast cancer: a multicenter real-world data analysis. Ralser DJ; Kiver V; Solomayer EF; Neeb C; Blohmer JU; Abramian AV; Maass N; Schütz F; Kolberg-Liedtke C; Müller C; Rambow AC Arch Gynecol Obstet; 2024 Oct; ():. PubMed ID: 39373732 [TBL] [Abstract][Full Text] [Related]
2. CDK4/6 Inhibitors in Advanced HR+/HER2 - Breast Cancer: A Multicenter Real-World Data Analysis. Müller C; Kiver V; Solomayer EF; Wagenpfeil G; Neeb C; Blohmer JU; Abramian AV; Maass N; Schütz F; Kolberg-Liedtke C; Ralser DJ; Rambow AC Breast Care (Basel); 2023 Feb; 18(1):31-41. PubMed ID: 36876172 [TBL] [Abstract][Full Text] [Related]
3. Prognosis in HR-positive metastatic breast cancer with HER2-low versus HER2-zero treated with CDK4/6 inhibitor and endocrine therapy: a meta-analysis. Xia LY; Cao XC; Hu QL; Xu WY Front Oncol; 2024; 14():1413674. PubMed ID: 39267829 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer. Turner S; Chia S; Kanakamedala H; Hsu WC; Park J; Chandiwana D; Ridolfi A; Yu CL; Zarate JP; Rugo HS Oncologist; 2021 Jul; 26(7):e1133-e1142. PubMed ID: 33909934 [TBL] [Abstract][Full Text] [Related]
6. Clinical benefit and safety profile of cross-line therapy with CDK4/6 inhibitors: a retrospective study of HR+/HER2- advanced breast cancer. Zhao Q; Jiang M; Liu J; Zhang M; He M; Zhou S; Wang J; Mo H; Lan B; Yuan P; Zhang P; Ma F; Li Q; Xu B Cancer Biol Med; 2024 Sep; 21(10):934-50. PubMed ID: 39267478 [TBL] [Abstract][Full Text] [Related]
7. CDK4/6 inhibitors versus weekly paclitaxel for treatment of ER+/HER2- advanced breast cancer with impending or established visceral crisis. Behrouzi R; Armstrong AC; Howell SJ Breast Cancer Res Treat; 2023 Nov; 202(1):83-95. PubMed ID: 37584881 [TBL] [Abstract][Full Text] [Related]
8. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. Schneeweiss A; Ettl J; Lüftner D; Beckmann MW; Belleville E; Fasching PA; Fehm TN; Geberth M; Häberle L; Hadji P; Hartkopf AD; Hielscher C; Huober J; Ruckhäberle E; Janni W; Kolberg HC; Kurbacher CM; Klein E; Lux MP; Müller V; Nabieva N; Overkamp F; Tesch H; Laakmann E; Taran FA; Seitz J; Thomssen C; Untch M; Wimberger P; Wuerstlein R; Volz B; Wallwiener D; Wallwiener M; Brucker SY Breast; 2020 Dec; 54():88-95. PubMed ID: 32956934 [TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy of CDK4/6 inhibitor plus endocrine therapy in HR-positive/HER2-0 and HER2-low-positive metastatic breast cancer: a secondary analysis of PALOMA-2 and PALOMA-3 trials. Li H; Wu Y; Zou H; Koner S; Plichta JK; Tolaney SM; Zhang J; He YW; Wei Q; Tang L; Zhang H; Zhang B; Guo Y; Chen X; Li K; Lian L; Ma F; Luo S EBioMedicine; 2024 Jul; 105():105186. PubMed ID: 38861871 [TBL] [Abstract][Full Text] [Related]
10. Case report: Pan B; Hao Z; Xu Y; Wang Z; Yao R; Wang X; Ren C; Zhou Y; Sun Q; Huo L Front Oncol; 2022; 12():1095779. PubMed ID: 36620595 [TBL] [Abstract][Full Text] [Related]
11. Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316). Futamura M; Nakayama T; Yoshinami T; Oshiro C; Ishihara M; Morita M; Watanabe A; Tanigichi A; Tsukabe M; Shimoda M; Nitta K; Chihara Y; Yasojima H; Ouchi Y; Tokumaru Y; Masuda N Breast Cancer; 2023 Nov; 30(6):943-951. PubMed ID: 37486454 [TBL] [Abstract][Full Text] [Related]
12. Exploring the Clinical Impact of RANK Pathway Inhibition in Advanced Breast Cancer: Insights From a Retrospective Study on CDK4/6 Inhibitors and Antiresorptive Therapy. Akdag G; Dogan A; Yildirim S; Kinikoglu O; Mokresh ME; Alomari O; Turkoglu E; Isik D; Sürmeli H; Basoglu T; Sever ON; Odabas H; Yildirim ME; Turan N Cureus; 2024 Jun; 16(6):e63362. PubMed ID: 39070363 [TBL] [Abstract][Full Text] [Related]
14. Real-world experience with CDK4/6 inhibitors in hormone receptor-positive metastatic and recurrent breast cancer: findings from an Asian population. Chen BF; Tsai YF; Chao TC; Lien PJ; Lin YS; Feng CJ; Chen YJ; Cheng HF; Liu CY; Lai JI; Tseng LM; Huang CC Clin Exp Med; 2024 Aug; 24(1):185. PubMed ID: 39133334 [TBL] [Abstract][Full Text] [Related]
15. Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy. Rozenblit M; Mun S; Soulos P; Adelson K; Pusztai L; Mougalian S Breast Cancer Res; 2021 Jan; 23(1):14. PubMed ID: 33514405 [TBL] [Abstract][Full Text] [Related]
16. Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort. Pla H; Felip E; Obadia V; Pernas S; Viñas G; Margelí M; Fort-Culillas R; Del Barco S; Sabaté N; Fort E; Lezcano C; Cirauqui B; Quiroga V; Stradella A; Gil Gil M; Esteve A; Recalde S Clin Transl Oncol; 2024 Jul; 26(7):1748-1758. PubMed ID: 38519708 [TBL] [Abstract][Full Text] [Related]
17. Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution study. Choong GM; Liddell S; Ferre RAL; O'Sullivan CC; Ruddy KJ; Haddad TC; Hobday TJ; Peethambaram PP; Liu MC; Goetz MP; Giridhar KV Breast Cancer Res Treat; 2022 Nov; 196(1):229-237. PubMed ID: 36045271 [TBL] [Abstract][Full Text] [Related]
18. Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR Bardia A; Hurvitz SA; DeMichele A; Clark AS; Zelnak A; Yardley DA; Karuturi M; Sanft T; Blau S; Hart L; Ma C; Rugo HS; Purkayastha D; Moulder S Clin Cancer Res; 2021 Aug; 27(15):4177-4185. PubMed ID: 33722897 [TBL] [Abstract][Full Text] [Related]
19. Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study. Yamashita T; Sohn JH; Tokunaga E; Niikura N; Park YH; Lee KS; Chae YS; Xu B; Wang X; Im SA; Li W; Lu YS; Aguilar CO; Nishijima S; Nishiyama Y; Sugihara M; Modi S; Tsurutani J Breast Cancer; 2024 Sep; 31(5):858-868. PubMed ID: 38884900 [TBL] [Abstract][Full Text] [Related]
20. Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups. Bardia A; Cortés J; Bidard FC; Neven P; Garcia-Sáenz J; Aftimos P; O'Shaughnessy J; Lu J; Tonini G; Scartoni S; Paoli A; Binaschi M; Wasserman T; Kaklamani V Clin Cancer Res; 2024 Oct; 30(19):4299-4309. PubMed ID: 39087959 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]